Emgality is a preventive treatment specifically developed to help give you more migraine-free days

Mother Daughter Sword Fight Image

As shown in two 6-month studies of adults who had 4-14 migraine days per month:

50% reduction graphic

In a 3-month study of adults with 15+ headache days per month, 28% had their monthly migraine days cut in half or more with Emgality compared to 15% who took placebo.

100% reduction graphic

In a 3-month study, the number of adults with 15+ headache days per month who were migraine-free in an average month did not differ between Emgality and placebo.


Share with a friend:


Select Important Safety Information
Emgality may cause allergic reactions, such as itching, rash, hives, and trouble breathing. Allergic reactions can happen days after using Emgality. Call your healthcare provider or get emergency medical help right away if you have any of the following symptoms, which may be part of an allergic reaction:

  • swelling of your face, mouth, tongue, or throat
  • trouble breathing

Ask your doctor if once-monthly Emgality is right for you

Emgality was specifically developed for migraine

Historically, many migraine preventive medicines were designed for other conditions. Emgality was specifically developed to bind to CGRP, a substance in the brain that may play a key role in migraine, and block its binding to the receptor.

MOA image

CGRP = calcitonin gene-related peptide.

Interested in discovering more? Sign up for the latest updates from Emgality

Purpose & Safety Summary
PURPOSE and SAFETY SUMMARY

Important Facts About Emgality® (em-GAL-it-ē) injection. Also known as galcanezumab-gnlm.
Emgality is a prescription medicine used for the preventive treatment of migraine in adults. The medicine comes in a prefilled pen or syringe and is taken once a month.

Warnings
Do not use Emgality if you are allergic to galcanezumab-gnlm or any of the ingredients in Emgality.
Emgality may cause allergic reactions, such as itching, rash, hives, and trouble breathing. Allergic reactions can happen days after using Emgality. Call your healthcare provider or get emergency medical help right away if you have any of the following symptoms, which may be part of an allergic reaction: swelling of your face, mouth, tongue, or throat, or trouble breathing.
Common side effects
The most common side effects of Emgality are injection site reactions.
These are not all the possible side effects of Emgality. Tell your doctor if you have any side effects.
You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Before using
Before you use Emgality, discuss these questions with your doctor:
❑ Do you have other medical conditions?
❑ Do you take other medicines? Tell your doctor about all the prescription and over-the-counter drugs, vitamins, and herbal supplements you take.
Tell your doctor if:
❑ You are pregnant or breastfeeding.
❑ You are under age 18. It is not known if Emgality is safe and effective in children.
How to take
  • Read the Instructions for Use that come with Emgality. There you will find information about how to store, prepare, and inject Emgality.
  • Use Emgality exactly as your doctor says.
  • If you miss a dose, inject it as soon as possible. Then continue to take it once a month from the date of your last dose.
Learn more
For more information, call 1-833-EMGALITY (1-833-364-2548) Monday - Friday, 9AM - 8PM EST.
This summary provides basic information about Emgality, but it does not include all information known about this medicine. Read the information that comes with your prescription every time you have a prescription filled. Talk to your doctor or pharmacist about this information. Your doctor is the best person to help you decide if Emgality is right for you.
Emgality® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. ©Lilly USA, LLC 2018. All rights reserved.
C-GZ-US-0290
Please see Full Prescribing Information, including Patient Information for Emgality. See Instructions for Use included with the pen and prefilled syringe.